NEW YORK, NY / ACCESSWIRE / February 20, 2018 / U.S. markets closed Friday with weekly gains in the range of 4 percent to 5 percent. The Dow Jones Industrial Average gained 0.08 percent to close at 25,219.38, while the S&P 500 increased 0.04 percent to close at 2,732.22. Both, Dow and S&P 500 were up 4.3 percent for the week. The Nasdaq Composite Index dropped 0.23 percent to close at 7,239.47, however posting weekly gains of 5.3 percent. With trading closed on Monday to celebrate President's Day, investors had some time to analyze recent events.
“Events over the past few weeks serve as a salutary reminder of both the dangers of crowded positions and of the power of technical forces when combined with consensual positioning,” said Erin Browne, head of asset allocation at UBS.
RDI Initiates Coverage on:
GlaxoSmithKline's stock moved 1.05% higher Friday, to close the day at $37.70. The stock recorded a trading volume of 4,690,046 shares, which was below its three months average volume of 5,107,626 shares. In the last year, GlaxoSmithKline's shares have traded in a range of 34.52 - 44.54. The stock is currently trading 15.36% below its 52 week high. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $37.35 is below its 200-day moving average of $37.92. Shares of GlaxoSmithKline are trading at a Price to Earnings ratio of 43.84. Shares of GlaxoSmithKline have fallen roughly 1.31 percent in the past month and are up 6.29 percent year-to-date.
Access RDI’s GlaxoSmithKline PLC Research Report at:
On Friday, shares of Astrazeneca recorded a trading volume of 4,256,950 shares, which was above the three months average volume of 3,686,467 shares. The stock ended the day 0.26% lower at 33.93. The share price has gained 19.35% from its 52 week low with a 52 week trading range of 28.43 - 36.70. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $35.13 is greater than its 200-day moving average of $33.23. Shares of the company are trading at a Price to Earnings ratio of 28.63. Shares of Astrazeneca have fallen roughly 4.26 percent in the past month and are down 2.22 percent year-to-date.
Access RDI’s Astrazeneca PLC Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.